CA-MATRIXX-SOFTWARE
3.5.2021 12:04:58 CEST | Business Wire | Press release
MATRIXX Software , a global leader in cloud native, 5G monetization solutions, today announced performance results from its IBM Cloud for Telecommunications implementation. Anticipating the urgent need of Communications Service Providers (CSPs) to monetize their 5G investments, MATRIXX Software’s 5G CCS established a performance milestone of 200K transactions per second (TPS) across 100M subscribers running on IBM Cloud for Telecommunications.
With average end-to-end latency of 7.4 milliseconds across all operations, including network gateways and routing, this performance benchmark demonstrates that MATRIXX on IBM Cloud can enable CSPs to run critical network workloads in the cloud at the same or better performance levels as on-premise. MATRIXX successfully delivered seamless scalability for an efficient, flexible cloud native charging solution, which opens the door for CSPs to experiment with new ways of monetizing 5G workloads.
This is an important milestone as 5G represents a $667B opportunity by 2026 and impacts every industry. To explore and test new revenue streams, CSPs need to accelerate their network transformation to handle increased traffic from new services and devices. With more than 30 billion IoT devices predicted by 2025, telco networks and IT infrastructure will need proven capability to scale both vertically and horizontally if they are to manage the 10-20x growth in traffic anticipated from 5G.
Using a simulated blend of 4G and 5G traffic, MATRIXX used the IBM Cloud for Telecommunications, built on Red Hat OpenShift, to provide more flexibility in harnessing data across cloud and on-premises environments. The performance benchmark demonstrates how together, MATRIXX and IBM Cloud for Telecommunications can deliver consistent throughput and latency, which helps enable providers to run critical network workloads such as charging in the cloud.
“As telcos deploy 5G network infrastructure, they are looking for validation of new revenue models that 5G enables,” said Marc Price, MATRIXX CTO. “We have collaborated with IBM to achieve industry-leading metrics on its IBM Cloud for Telecommunications, showcasing for CSPs how their 5G monetization strategies will be achievable as the number and diversity of connected devices increases exponentially.”
This is the first lab outcome since MATRIXX joined IBM’s partner ecosystem. These results demonstrate the seamless scalability of MATRIXX’s patented converged charging technology when combined with the IBM Cloud for Telecommunications. Working in close collaboration, IBM’s Hybrid Cloud Build Team and MATRIXX have developed a blueprint for best practices and configuration requirements they can deliver to CSP’s to address their unique performance targets.
“As 5G transforms the telco industry, many operators face the challenge of managing growing volumes of data, voice, and multi-media services from millions of end users. The IBM Cloud for Telecommunications is designed to address these specific challenges and transform their networks into flexible platforms that can efficiently scale,” said Steve Goetz, Vice President & Senior Partner of Global Telecommunications, Media & Entertainment Industry at IBM. “As a leading Network and 5G Transformation partner, IBM Global Business Services is proud to support our ecosystem partner MATRIXX to help them achieve such a notable milestone. These results will accelerate business transformation and agility as customers modernize enterprise applications and infrastructure to unlock the power of 5G and edge.”
With innovations in business rule execution, transaction processing, data management and clustering, the cloud native MATRIXX 5G CCS delivers consistent throughput and latency within heterogenous network environments, managing sophisticated price plans, across hundreds of millions of unique subscribers and devices.
MATRIXX is part of IBM's partner ecosystem collaborating on the IBM Cloud for Telecommunications to help network equipment providers, independent software vendors (ISVs), software-as-a-service providers, and hardware partners accelerate business transformation by unlocking the power of 5G and edge. The IBM Cloud for Telecommunications is an open, hybrid cloud architecture that leverages Red Hat OpenShift and IBM Cloud Satellite to enable clients to deploy IBM Cloud services anywhere: on the cloud, on premises or at the edge, while addressing unique industry regulatory and security requirements. The IBM Hybrid Cloud Build Team is an elite team dedicated to help partners maximize the value of open hybrid cloud environments and unlock the power of AI for their business and customers.
To learn more about the collaboration between MATRIXX and IBM, watch this video interview between Marc Price and Omkar Nimbalkar, VP WW Hybrid Cloud Build Team at IBM Hybrid Cloud Ecosystem Group.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS), enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005238/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom